Fortum

(redirected from Fortum Corporation)

ceftazidime

Fortaz, Fortum (UK), Tazicef

Pharmacologic class: Third-generation cephalosporin

Therapeutic class: Anti-infective

Pregnancy risk category B

Action

Interferes with bacterial cell-wall synthesis and division by binding to cell wall, causing cell to die. Active against gram-negative and gram-positive bacteria, with expanded activity against gram-negative bacteria. Exhibits minimal immunosuppressant activity.

Availability

Powder for injection: 500 mg, 1 g, 2 g, 6 g

Premixed containers: 1 g/50 ml, 2 g/50 ml

Indications and dosages

Skin infections; bone and joint infections; urinary tract and gynecologic infections, including gonorrhea; respiratory tract infections; intraabdominal infections; septicemia
Adults and children ages 12 and older: For most infections, 500 mg to 2 g I.V. or I.M. q 8 to 12 hours. For pneumonia and skin infections, 0.5 to 1 g I.V. or I.M. q 8 to 12 hours. For bone and joint infections, 2 g I.V. or I.M. q 12 hours. For severe and life-threatening infections, 2 g I.V. q 8 hours. For complicated urinary tract infections (UTIs), 500 mg q 8 to 12 hours. For uncomplicated UTIs, 250 mg I.M. or I.V. q 12 hours.
Children ages 1 month to 12 years: 30 to 50 mg/kg I.V. q 8 hours
Neonates younger than 4 weeks: 30 mg/kg I.V. q 12 hours

Dosage adjustment

• Renal impairment

Off-label uses

• Febrile neutropenia
• Prophylaxis of perinatal infections

Contraindications

• Hypersensitivity to cephalosporins or penicillins

Precautions

Use cautiously in:
• renal impairment, hepatic disease, biliary obstruction, phenylketonuria
• history of GI disease
• elderly patients
• pregnant or breastfeeding patients
• children.

Administration

• Obtain specimens for culture and sensitivity testing as necessary before starting therapy.
• Reconstitute powder for injection with sterile water, following manufacturer's directions for amount of diluent to use.
• For I.V. injection, dilute in sterile water as directed, and give single dose over 3 to 5 minutes. Inject into large vein; rotate injection sites.
• For intermittent I.V. infusion, dilute further with 100 ml of sterile water or another compatible fluid, such as normal saline solution or dextrose 5% in water. Infuse over 30 minutes.
• Don't dilute with sodium bicarbonate.
• For I.M. injection, reconstitute with sterile water, bacteriostatic water, or 0.5% or 1% lidocaine hydrochloride.
• When giving I.M., inject deep into large muscle mass.

Adverse reactions

CNS: headache, confusion, hemiparesis, lethargy, paresthesia, syncope, asterixis, neuromuscular excitability (with increased drug blood levels in renally impaired patients), seizures, encephalopathy

CV: hypotension, palpitations, chest pain, vasodilation

EENT: hearing loss

GI: nausea, vomiting, diarrhea, abdominal cramps, oral candidiasis, pseudomembranous colitis

GU: vaginal candidiasis, nephrotoxicity

Hematologic: lymphocytosis, eosinophilia, bleeding tendency, hemolytic anemia, hypoprothrombinemia, neutropenia, thrombocytopenia, agranulocytosis, bone marrow depression

Hepatic: hepatic failure, hepatomegaly

Musculoskeletal: arthralgia

Respiratory: dyspnea

Skin: urticaria, maculopapular or erythematous rash

Other: chills, fever, superinfection, I.M. site pain, anaphylaxis, serum sickness

Interactions

Drug-drug.Aminoglycosides, loop diuretics: increased risk of nephrotoxicity

Chloramphenicol: antagonism of ceftazidime's effects

Probenecid: decreased excretion and increased blood level of ceftazidime

Drug-diagnostic tests.Alanine aminotransferase, alkaline phosphatase, aspartate aminotransferase, bilirubin, blood urea nitrogen, creatinine, eosinophils, gamma-glutamyltransferase, lactate dehydrogenase: increased levels

Hemoglobin, platelets, white blood cells: decreased values
Coombs' test, urinary 17-ketosteroids, nonenzyme-based urine glucose tests (such as Clinitest): false-positive results

Drug-herbs.Angelica, anise, arnica, asafetida, bogbean, boldo, celery, chamomile, clove, danshen, fenugreek, feverfew, garlic, ginger, ginkgo, ginseng, horse chestnut, horseradish, licorice, meadowsweet, onion, papain, passionflower, poplar, prickly ash, quassia, red clover, turmeric, wild carrot, wild lettuce, willow: increased risk of bleeding

Patient monitoring

Monitor for extreme confusion, tonic-clonic seizures, and mild hemiparesis when giving high doses.
• Assess CBC and kidney and liver function test results.
• Monitor for signs and symptoms of superinfection and other serious adverse reactions.
• Be aware that cross-sensitivity to penicillins may occur.

Patient teaching

• Instruct patient to report reduced urine output, persistent diarrhea, bruising, and bleeding.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs, tests, and herbs mentioned above.

Fortum

A brand name for CEFTAZIDIME.
References in periodicals archive ?
Companies Mentioned in this Report: Fortum Corporation, Pohjolan Voima Oy
Fortum Corporation - Power Plants and SWOT Analysis, 2014 Update
Country: RussiaSector: UtilitiesTarget: Fortum's heating network in SurgutBuyer: Surgut City Grid LLCVendor: Fortum Corporation Type: DivestmentStatus: Agreed
Finnish energy company Fortum Corporation (OMX Helsinki:FUM1V) and forestry company Metsahallitus declared on Friday that they are jointly developing a wind power project in the Kuolavaara-Keulakkopaa area in Finnish Lapland.
Fortum (Helsinki:FUM1V), an energy products and services company, has named Alexander A Chuvaev as the General Director of the company's Russian subsidiary, OAO Fortum, and Executive Vice President of Fortum Corporation.
Prior to Ahlstrom, he worked in several managerial positions in the finance functions of Fortum Corporation and Outokumpu Group.
Finnish energy group Fortum Corporation said on Monday (23 August) that it had signed a five-year agreement with the US technology solutions provider HP on outsourcing of Fortum's IT infrastructure to HP.
ON AG of three regional electricity utilities controlled by Finnish group Fortum Corporation was approved by the European Commission on June 13 under the EU Merger Regulation.
Finnish power company Fortum Corporation (Helsinki: FUM1V) reported on Tuesday (28 April) a fall in net profit in the first quarter of 2009 to EUR406m from EUR452m in the first quarter of 2008.
Finnish energy group Fortum Corporation said on Tuesday (8 June) that it had entered into negotiations regarding outsourcing of its IT infrastructure in order to improve service levels, flexibility and cost efficiency.
The Finnish energy group Fortum Corporation (OMX Helsinki:FUM1V) reported on Thursday (5 February) an operating profit of EUR1,963m on sales of EUR5,636m for the year 2008.
Finnish-Swedish telecomms operator TeliaSonera AB said on Monday (19 January) that its Swedish subsidiary TeliaSonera Sweden, operating under the name Telia, had signed an agreement with Fortum Markets, a subsidiary of the Finnish energy group Fortum Corporation, to take over its voice and Internet customers on the Swedish market.